PICTON MAHONEY ASSET MANAGEMENT
Position in TMO — Thermo Fisher Scientific Inc.
CIK 1539041
Toronto, A6
Position in TMO
as of Jun 30, 2026
· filed Aug 13, 2026
Position Value
$8,410,815
-$13,483,405 QoQ
Shares Held
16,776
-62.3% QoQ
Ownership
0.005%
of shares outstanding
% of Portfolio
0.08%
of 13F equity value
Holder Rank
#692
of 2,617 holders
Holding Since
Mar 2020
8 quarters on record
Voting authority
Sole 100%
Shared 0%
None 0%
Common Shares in TMO Over Time
Shares Held
Position Value (USD)
Position in Diagnostics & Research
Healthcare · as of Jun 30, 2026PICTON MAHONEY ASSET MANAGEMENT holds $119,494,638 across 9 Diagnostics & Research names. TMO ranks #6 (7.0% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | GH |
Guardant Health, Inc.
|
191,876 | $28,787,156 | |
| 2 | CRL |
Charles River Laboratories International, Inc.
|
116,144 | $26,340,297 | |
| 3 | NTRA |
Natera, Inc.
|
76,415 | $20,742,851 | |
| 4 | A |
Agilent Technologies, Inc.
|
107,654 | $14,299,680 | |
| 5 | RDNT |
RadNet, Inc.
|
202,005 | $12,457,648 | |
| 6 | TMO |
Thermo Fisher Scientific Inc.
This page
|
16,776 | $8,410,815 | |
| 7 | WAT |
Waters Corp /De/
|
20,721 | $7,771,203 | |
| 8 | ILMN |
Illumina, Inc.
|
2,746 | $482,829 |
All Filings in TMO
Export CSV
8 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $8,410,815 | 16,776 | Shares | Sole | 2026-08-13 | |
| 2026-03-31 | $21,894,220 | 44,543 | Shares | Sole | 2026-05-13 | |
| 2025-12-31 | $26,341,217 | 45,459 | Shares | Sole | 2026-02-11 | |
| 2025-09-30 | $17,013,046 | 35,077 | Shares | Sole | 2025-11-12 | |
| 2020-12-31 | $26,355,229 | 56,583 | Shares | Sole | 2021-02-12 | |
| 2020-09-30 | $24,619,155 | 55,760 | Shares | Sole | 2020-11-02 | |
| 2020-06-30 | $23,405,352 | 64,595 | Shares | Sole | 2020-08-05 | |
| 2020-03-31 | $17,603,052 | 62,070 | Shares | Sole | 2020-05-06 | |
| No filing history on record for this holder in this stock. | ||||||